SYNTHESIS OF SOME PHENACYL DERIVATIVES OF 1-METHYL-7-METHOXY-β-CARBOLINE AND THEIR BEHAVIOURAL STUDY

Z.S. SAIFY, JAWAID FARHAD, NOUSHEEN MUSHTAQ, FOZIA NOOR, SHAMOONA TAKWEEN*, SHAMIM AKHTAR, WAQAR HUSSAIN, SHAHEEN A. HUSSAIN** AND KHALID M. KHAN***

Department of Pharmaceutical Chemistry, *Department of Pharmacology, Faculty of Pharmacy, University of Karachi, Karachi-75270, Pakistan **PCSIR Laboratories, Karachi, Pakistan ***HEJ Research Institute of Chemistry, University of Karachi, Karachi-75270, Pakistan.

ABSTRACT:

In the present study two phenacyl derivatives of Harmaline; 2-(7-Methoxy-1-methyl-1,3,4,9-tetrahydro- β -carbolin-2-yl)-1-(3-nitro-phenyl)-ethanone and 1-(3,4-Dihydroxy-phenyl)-2-(7-methoxy-1-methyl-1,3,4,9-tetrahydro- β -carbolin-2-yl)-ethanone were synthesized and evaluated for their effect on behaviour of mice, only meta-nitro phenacyl derivative showed activity, which can be compared with parent compound.

INTRODUCTION

Harmaline (1-methyl-7-methoxy-β-carboline) have been received enormous attention because of invaluable therapeutic activities. Carboline and its related compounds have been isolated from plants like Banisteria caapi, Peganum hermala, Prestonia amazonicum and number of other plants. Recently different new alkaloids were reported in literature having beta carboline ring system (Harwood et al., 2003 and Samoun et al., 2002) and different other carboline alkaloids found in food were studied for their antioxidant activity (Herraiz et al., 2002). Different kinds of derivatives having carboline ring system have also been synthesized and they exhibited pronounced pharmacological and biological effects (Maw et al., 2003 and Park et al., 2003). Carboline containing moieties were found effective on CNS (Kitajima et al., 2002, Fuentes et al., 1971, Tonks, 2003, Boksa et al., 2001, Pokk & Vali, 2001, Krazem et al., 2001 and Suaudeau et al., 2000), smooth muscles (Shi et al., 2001), cardiovascular system (Aarons et al., 1977, Shi et al., 2001, Khawaja et al., 1978 and Riba et al., 2003) and vision (Rojas et al., 1971) as well as platelet binding activity was also evaluated (Given & Longenecker, 1983). Work has also been done on toxicity profile (Lamchouri et al., 2002), antitumour activity (Fontona et al., 2002 and Ishida et al., 1999) of different carboline analogues and the ability of different microbes to transform the carboline containing alkaloids (Herath et al., 2003). The potentials of carboline ring system as significant therapeutic agent led to study different synthesized derivatives for their biological activity.

EXPERIMENTAL

Synthesis

Reagents, Chemicals and Instruments:

Reagents were purchased from Aldrich Chemical Company. All solvents are reagents grade. Reactions were monitored by TLC using silica gel type 60 P_{254} of E. Merk for preparing TLC plates and visualized with iodine vapours. All melting points were recorded on Gallenkamp melting point apparatus and are uncorrected. Solid calcium sulphate from E. Merk was used for drying reaction product after workup. Ultraviolet (UV) spectra were recorded in methanol on a Hitachi U-3200 spectrophotometer. Infra Red (IR) spectra were measured on a Shimadzu IR 460 spectrophotometer using KBR disc. Mass Spectra (MS) were determined on Varian Massen spektrometer MAT 311A spectrometer. Nuclear Magnetic Resonance (NMR) spectra were recorded in DMSO-d₆ on Bruker AM-300 and 400 spectrometer operating at 300 and 400 MHz.

General Method

Equimolar quantities of 1-methyl-7-methoxy- β -carboline and substituted phenacyl halides were dissolved in acetone (75ml) separately. They were mixed and stirred for 4-6 hours at room temperature. The reaction mixtures were refluxed for 48-72 hours and kept in dark for 3-5 days. Reactions were continuously monitored with TLC. The products were recrystallized from appropriate solvents to give the purified products.



Characterization of Compounds:

2-(7-Methoxy-1-methyl-1,3,4,9-tetrahydro-β-carbolin-2-yl)-1-(3-nitro-phenyl)-ethanone (I)State:Orange needle shaped crystalsMelting Point: $230 \pm 2^{\circ}$ CYield:71%

UV λ_{max} (MeOH) nm; 372, 262. IR ν_{max} (KBr) cm⁻¹: 460, 3120,1720, 1630, 1580, 1550, 1218. ¹HNMR (d₆-DMSO, 400MHz): δ 2.48 (m, 1H, *H*-1), 2.63 (s, 2H, *CH*2), 3.1 (t, 2H, *J*= 8.61, *H*-3, *H*-3'), 3.2 (m, 2H, *H*-4, *H*-4'), 3.84 (s, 3H, *CH*3) 4.5 (d, 3H, *J*=7.0, *CH*3), 6.81 (dd, 2H, *J*=8.90, *J*=2.11, *H*-6, *H*-5') 6.87 (dd, 2H, *J*=7.97, *J*=2.2, *H*-8, H-6'), 6.85 (dd, 2H, *J*=8.90, *J*=2.0, *H*-2', *H*-4') 7.65 (d, 1H, *J*=8.8, *H*-5), 12.18 (s, 1H, *H*-9)

1-(3,4-Dihydroxy-phenyl)-2-(7-methoxy-1-methyl-1,3,4,9-tetrahydro-β-carbolin-2-yl)-ethanone (II)

State:	Grey crystalline powder
Melting Point:	$242 \pm 2^{\circ}C$
Yield:	65%

UV λ_{max} (MeOH) nm; 386, 252; IR ν_{max} (KBr) cm⁻¹:3475, 3180, 1710, 1630, 1300, 1230. ¹HNMR (d₆-DMSO, 400MHz): δ 2.48 (d, 3H, *J*=7.2, *CH*3), 2.4 (m, 2H, *H*-4, *H*-4'), 2.49-2.50 (m, 1H, *H*-1), 3.2(t, 2H, *J*=9.10, *H*-3, *H*-3'), 3.40 (s, 2H, *CH*2), 3.84 (s, 3H, *CH*3), 6.83 (dd, 2H, *J*=6.84, *J*= 2.15, *H*-6, *H*-5'), 6.80 (dd, 2H, *J*=8.9 *J*=2.11, *H*-8, *H*-6'), 6.91 (dd, 1H, *J*= 19.92, *J*=2.22, *H*-2') 7.69 (d, 1H, *J*=8.9, *H*-5), 11.83 (s, 2H, *OH*), 12.69 (s, 1H, H-9).

Effect on CNS:

Animals:

Female albino mice +NMRI strain weighing 25-30 mg.

Drugs and Chemicals:

Harmaline (Merk), Test compounds, Water for injection, DMSO of Merk

Method:

For experiment, animals were divided into four groups, (n=6), among which one group served as control. (water for injection/2% DMSO). Test compounds were administered *i.p.* at the dose of 50mg/kg. The effect of parent compound and synthetic derivatives on behaviour was observed.

RESULT AND DISCUSSION

Effect of the parent and synthetic compounds is given in the Table.

 Table

 Showing the effect of 1-methyl-7-methoxy-β-carboline and its Phenacyl derivatives on mice behaviour

	Control	Harmaline (1-methyl-7- methoxy-β- carboline)	2-(7-Methoxy-1- methyl-1,3,4,9- tetrahydro-b- carbolin-2-yl)-1- (3-nitro-phenyl)- ethanone (I)	1-(3,4-Dihydroxy- phenyl)-2-(7- methoxy-1- methyl-1,3,4,9- tetrahydro-b- carbolin-2-yl)- ethanone (II)
Dose (mg/kg)	_	50	50	50
Route of administration	i.p.	i.p.	i.p.	i.p.
Time of onset (minutes)	_	10	10	_
Time of duration (minutes)	_	120	130	_
Tremor	_	++++	+++	_
CNS stimulation	_	+++	+++	_
Aggressive behaviour	_	+++	+++	_
Increased motility	_	++	+++	_

During investigation mice treated with parent compound (1-methyl-7-methoxy- β -carboline) possessed extreme hyperactivity and on touch became aggressive, the motility of animal increased. Harmaline is a powerful stimulating agent and causes excitation of central nervous system. Compound induced tremor (generalized convulsions) within 10 minutes, which persisted for two hours.

 $2-(7-Methoxy-1-methyl-1,3,4,9-tetrahydro-\beta-carbolin-2-yl)-1-(3-nitro-phenyl)-ethanone$ (I) produced severe tremors within ten minutes, which lasted for more than two hours. They showed CNS excitation and possessed hyperactivity with loss of conditioned response. Motility of animals increased and they showed aggressive response on touch.

In the case of $1-(3,4-Dihydroxy-phenyl)-2-(7-methoxy-1-methyl-1,3,4,9-tetrahydro-\beta-carbolin-2-yl)-ethanone (II) no effect was observed though the compound was found inactive apparently but the compound can be studied further for CNS effect by neurochemical estimation.$

Comparing the activity of synthesized derivatives with parent compound only compound (I) exhibited significant effect and showed more or less the same response as observed by parent compound with same time of onset and duration of action. This result showed that by adding phenacyl halide having meta nitro group did not change the activity and retain the effect of parent compound. Significant activity of compound (I) and no effect by compound (II) is also very interesting because SAR of two compounds revealed that by removing NO₂ group of phenyl ring of phenacyl moiety and incorporating OH group in the same phenyl ring make the compound inactive. These results may suggest that substitution in the phenyl ring is responsible for significant effect in compound (I) and no response for compound (II).

The present study is only the preliminary screening and results are encouraging enough and will provide a better understanding for exploration of different biological fronts to get a compound with profound therapeutic activity.

REFERENCES

- Aarons, D.H., Rossi, G.V. and Orzechwoski, R.F. (1977). Cardiovascular action of three harmala alkaloids; Harmine, Harmaline and Harmalol. J. Pharm. Sci. 66(9): 1244-1248.
- Boksa, J., Mokrosz, M.J. and Charakchieva-Minol, S. (2001). 2-H- and 2-acyl-9-[omega[4-(2-methoxyphenyl)piperazinyl]-alkyl]-1,2,3,4-tetrahydrobeta-Carboline as ligands of 5-HT1A and 5-HT2A receptors. *Pol. J. Pharmacol.* **53**(5): 501-508.
- Fontona, A, Benito, E.J., Martin, M.J., Sanchez, N., Alajarin R. and Vaquero, J.J. (2002). Synthesis and Cytotoxic activity of Pyridazino[1',6',1,2]pyrido[3, 4-b] indole-5-inium derivatives as anticancer agents. *Bioorg. Med. Chem. Lell.* **12**(18): 2611-2614.
- Fuentes, J.A. and Lango, V.G. (1971). An investigation on the Central effects of Harmine, Harmaline and related beta-carboline. *Neuropharmacol.* **10**(1): 15-23.
- Given, M.B. and Longenecker, G.L. (1983). Tetrahydroisoquinolines and beta-carboline specific binding to human platelet alpha 2 receptors *in vitro*. *Res. Commun. Chem. Pathol. Pharmacol.* 41(2): 349-352.
- Harwood, D.T, Urban, S. and Blunt, J.W. (2003). Beta-Carboline alkaloids from a new Zealand marine bryozoan, *Cribricellina cribraria*. *Nat. Prod. Res.* **17**(1): 15-19.
- Herath, W., Mikell, J.R., Ferreira, D. and Khan, I.A. (2003). Microbial metabolites of Harman alkaloids. *Chem. Pharm. Bull.* (Tokyo). **51**(6): 646-648.

- Herraiz, T. and Galisto, J. (2002). Tetrahydro-beta-carboline alkaloids that occur in food and biological system act as radical scavengers and antioxidants in ABST assay. *Free Radic. Res.* 36(8): 923-928.
- Ishida, J., Wang, H.K. and Bastow, K.F. (1999). Antitumour agents 201. Cytotoxicity of harmine and beta carboline analogues. *Biourg. Med. Chem. Lett.* 9(23): 3319-3324.
- Khawaja, O.U. and Yusuf, S.M. (1978). Pharmacological studies of nitroharmidine nitrate on cardiovascular system. J. Pak. Med. Assoc. 28(11): 162-168.
- Kitajima, M., Yokoya, M., Takayama, H. and Aimi, N. (2002). Synthesis and absolute configuration of new 3, 4 dihydro-beta-carboline type alkaloids, 3,4-dehydro-5-(s)-5-carboxy strictosidine, isolated from Peruvian Una de Gato (*Uncaria tomentosa*). Chem. Pharm. Bull (Tokyo). 50(10): 1376-1378.
- Krazem, A., Borde, N. and Beracochea, D. (2001). Effect of Diazepam and beta-CCM on working memory in mice relationship with emotional reactivity; *Pharmacol., Biochem. Behav.* 68(2): 235-244.
- Lamchouri, F., Settaf, A., Cherrah, Y. and El Hamidi, M. (2002). Experimental toxicity of Peganum harmala seeds. Ann. Pharm. Fr. 60(2): 123-129.
- Maw, Gn, Allerton, C.M. and Gbekor, E. (2003). Design Synthesis and biological activity of betacarboline based type-5 phosphodiestrase inhibitors. *Bioorg. Med. Chem. Lett.* 13(8): 1425-1428.
- Park, T.H., Kwon, O.S, Park, S.Y., Han, Es and Lee C.S. (2003). N-methylated beta carboline protect PC12 cells from cytotoxic effect of MPP(+) by attenuation of mitochondrial membrane permeability change. *Neurosci. Res.* 46(3): 349-358.
- Pokk, P. and Vali, M. (2001). The effect of Flumazenil, Ro 154513 and beta-CCM on the behaviour of control and stressed mice in staircase test. J. Psychopharmacol. 15(3): 155-159.
- Riba, J., Valle, M. and Urbano, G. (2003). Human Pharmacology of ayahusca; subjective and cardiovascular effects monoamine metabolite excretion and pharmacokinetics. J. Pharmacol. Exp. Ther. 306(1): 78-83.
- Rojas, A., Herrara, J., Delpiano, M. and Riobo, F. (1971). Effects of Harmaline on visual system of the rat. Vision Res. 3(Suppl.): 437-445.
- Salmoun, M., Devijver, C., Daloze, D., Braekman, J.C. and VanSoest, R.W. (2002). 5-Hydroxy Tryptamine derived alkaloids from marine sponges of the genus Hyrtios. J. Nat. Prod. 65(8): 1173-1176.
- Shi, C.C., Liao, J.F. and Chen, C.F. (2001). Spasmolytic effects of three harmala alkaloids on guinea pig isolated trachea. *Pharmacol. Toxicol.* 89(5): 259-264.
- Shi, C.C., Liao, J.F. and Chen, C.F. (2001). Comparative study on the vasorelaxant effects of three harmala alkaloids in vitro. Jpn. J. Pharmacol. 85(3): 299-305.
- Suaudeau, C., Rinaldi, D., Lepicard, E., Venault, P., Crusio, W.E. and Costentin, J. (2000). Divergent levels of anxiety in mice selected for differences in sensitivity to a convulsant agent. *Physiol. Behav.* 71(5): 517-523.
- Tonks, A. (2003). Treating generalized anxiety disorder; BMJ 326(7391): 700-702.